Delving into the Latest Updates on Bristol-Myers Squibb Pharma EEIG with Synapse

主要目的：评价CC-486维持治疗与安慰剂相比是否可改善首次达到完全缓解（CR）或血细胞计数未完全恢复的完全缓解（CRi）的急性髓系白血病（AML）患者的无复发生存期（RFS）；次要目的：确定CC-486维持治疗与安慰剂相比对首次达到CR/CRi的AML受试者的总生存期（OS）的影响；确定CC-486维持治疗与安慰剂相比对首次达到CR/CRi的AML受试者其他疗效终点的影响；评估CC-486在AML受试者中的安全性和耐受性；表征CC-486在AML受试者中的药代动力学；评价骨髓中残留病灶的预后和治疗意义；确定CC-486与安慰剂相比对健康相关生活质量（HRQoL）和医疗资源利用的影响

开始日期2022-08-19

申办/合作机构

新基医药咨询（上海）有限公司

[+3]

CTR20212323 / Active, not recruiting临床2期

纳武利尤单抗联合伊匹木单抗对比化疗治疗一线胸膜间皮瘤

主要目的：评估纳武利尤单抗联合伊匹木单抗与培美曲塞联合顺铂或卡铂方案作为一线疗法治疗中国不可切除恶性胸膜间皮瘤参与者的OS。次要目的：评估纳武利尤单抗联合伊匹木单抗和培美曲塞联合顺铂或卡铂作为一线疗法治疗中国不可切除胸膜间皮瘤参与者的ORR（通过研究者确定），PFS，安全性和耐受性。

开始日期2022-01-25

申办/合作机构

百时美施贵宝（中国）投资有限公司

[+4]

100 项与 Bristol-Myers Squibb Pharma EEIG 相关的临床结果

登录后查看更多信息

0 项与 Bristol-Myers Squibb Pharma EEIG 相关的专利（医药）

登录后查看更多信息

1

项与 Bristol-Myers Squibb Pharma EEIG 相关的文献（医药）

2019-03-01·European Journal of Cancer1区 · 医学

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children

1区 · 医学

Article

作者: Norga, Koenraad ; Adamson, Peter ; Pearson, Andrew D J ; Vezan, Remus ; Vassal, Gilles ; Bhargava, Pankaj ; Burke, Amos ; Klapper, Wolfram ; Miles, Rodney R ; Scobie, Nicole ; Ligas, Franca ; Schrappe, Martin ; Bollard, Catherine M ; Nottage, Kerri ; Burkhardt, Birgit ; Buechner, Jochen ; Zugmaier, Gerhard ; Marcus, Robert ; Minard-Colin, Veronique ; Kim, Su Young ; Horton-Taylor, Danielle ; Bolotin, Ellen ; Bomken, Simon ; Weiner, Susan ; Egorov, Anton ; Balakumaran, Arun ; Lesa, Giovanni ; Sterba, Jaroslav ; Copland, Christopher ; Gross, Thomas ; Pacaud, Lida ; Chiodin, Davy ; Ricafort, Rosanna ; Farhan, Mahdi ; Caron, Hubert ; Marshall, Lynley V ; Benettaib, Bouchra ; Reaman, Gregory ; Demolis, Pierre

Paediatric Strategy Forums have been created by the multistakeholder organisation, ACCELERATE, and the European Medicines Agency to facilitate dialogue between all relevant stakeholders and suggest strategies in critical areas of paediatric oncology drug development. As there are many medicines being developed for B-cell malignancies in adults but comparatively few in children with these malignancies, a Paediatric Strategy Forum was held to discuss the best approach to develop these products for children. It was concluded that as current frontline therapy is highly successful, despite associated acute toxicity, de-escalation of this or substitution of presently used drugs with new medicines can only be undertaken when there is an effective salvage regimen, which is currently not available. Therefore priority should be given to developing treatment for patients with relapsed and refractory mature B-cell lymphomas. The consensus of the clinicians attending the meeting was that CAR T-cells, T-cell engagers and antibody drug conjugates (excluding those with a vinca alkaloid-like drug) presently have the greatest probability of providing benefit in relapse in view of their mechanism of action. However, as producing autologous CAR T-cells currently takes at least 4 weeks, they are not products which could be quickly employed initially at relapse in rapidly progressing mature B-cell malignancies but only for the consolidation phase of the treatment. Global, industry-supported, academic-sponsored studies testing compounds from different pharmaceutical companies simultaneously should be considered in rare populations, and it was proposed that an international working group be formed to develop an overarching clinical trials strategy for these disease groups. Future Forums are planned for other relevant paediatric oncologic diseases with a high unmet medical need and relevant molecular targets.

100 项与 Bristol-Myers Squibb Pharma EEIG 相关的药物交易

登录后查看更多信息

100 项与 Bristol-Myers Squibb Pharma EEIG 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

23

6

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

艾基维仑赛 ( BCMA )	多发性骨髓瘤更多	批准上市
恩替卡韦 ( RT )	慢性乙型肝炎更多	批准上市
来那度胺 ( CK1α x CRBN x IFNγ x IKZF1 x IKZF3 x IL-2 x IL-6 x TNF-α )	输血依赖性贫血更多	批准上市
利基迈仑赛 ( CD19 )	原发性纵隔大B细胞难治性淋巴瘤更多	批准上市
纳武利尤单抗/瑞拉利单抗 ( LAG3 x PD-1 )	不可切除的黑色素瘤更多	批准上市